Showing 1981-1990 of 5627 results for "".
- Zeiss Celebrates 175 Years in Opticshttps://modernod.com/news/zeiss-celebrates-175-years-in-optics/2480468/This year, Zeiss celebrates its 175th year in business. Since the early days when Carl Zeiss created his first microscope, Zeiss has played a leading role in advancing the field of optics. From pioneering surgical microscopes and slit lamps, to developing optical glass and precision eye
- Santen to Introduce First Plant-Derived Eye Drop Bottle in EMEA to Help Reduce Reliance on Fossil Fuel-Based Plastichttps://modernod.com/news/santen-to-introduce-first-plant-derived-eye-drop-bottle-in-emea-to-help-reduce-reliance-on-fossil-fuel-based-plastic/2480457/Santen unveiled plans to launch t
- Hydrus Microstent Lowers Visual Field Loss by 47%, According to New 5-Year Pivotal Trial Datahttps://modernod.com/news/hydrus-microstent-lowers-visual-field-loss-by-47-according-to-new-5-year-pivotal-trial-data/2480443/Ivantis, developer of the Hydrus Microstent, announced new data from its 5-year HORIZON t
- Quantel Medical Launches Website Dedicated to Laser Therapies for Retinal Disordershttps://modernod.com/news/quantel-medical-launches-website-dedicated-to-laser-therapies-for-retinal-disorders/2480357/Quantel Medical announced its new website, www.subliminal-laser-therapy.com, dedicated to laser therapies for retinal disorders. "Over the years, the development and introduction of new and innovative laser technologies has
- Amidst the COVID-19 Pandemic, Early Intervention Remains an Obstacle for Overall Eye Health Despite Fear of Blindnesshttps://modernod.com/news/amidst-the-covid-19-pandemic-early-intervention-remains-an-obstacle-for-overall-eye-health-despite-fear-of-blindness/2480352/Globally, most adults, 70 percent, don’t plan to get their eyes examined this year, despite acknowledging the critical importance of eye health. These new findings come from a comprehensive, large-scale Johnson & Johnson Vision Global Eye Health Survey announced in advance of World Sigh
- ARVO Women’s Leadership Development Program Welcomes Class of 2021https://modernod.com/news/arvo-womens-leadership-development-program-welcomes-class-of-2021/2479483/The Association for Research in Vision and Ophthalmology (ARVO) recognized the 2021 class of its Women’s Leadership Development Program (WLDP). The program, provided through the support of Aerie Pharmaceuticals, is an interactive, year-long learning experience focused on leadership skill developm
- Glaucoma Devices’ Expanding Role to Drive Double-Digit Market Growthhttps://modernod.com/news/glaucoma-devices-expanding-role-to-drive-double-digit-market-growth/2479465/Glaucoma surgical devices will see increased use in all stages of disease and in stand-alone glaucoma procedures over the next 5 years, as companies commercialize more devices designed to meet these needs, according to a Market Scope report. Market Scope expects the glaucoma surgical devi
- Horizon Therapeutics Partners With Olympic Gold Medalist Gail Devers to Raise Awareness of Graves’ Disease and Symptoms of Thyroid Eye Disease (TED)https://modernod.com/news/horizon-therapeutics-partners-with-olympic-goldmmedalist-gail-devers-to-raise-awareness-of-graves-disease-and-symptoms-of-thyroid-eye-disease-ted/2479357/For Graves’ Disease Awareness Month in July, Horizon Therapeutics is teaming up with track star and three-time Olympic gold medalist Gail Devers, who has been living with Graves’ disease and symptoms of Thyroid Eye Disease (TED) for more than 30 years. Horizon and Ms. Devers are collaborating wit
- International Sports Vision Association and Macuhealth Offer New Educational Resource on Sports Nutrition for Your Eyeshttps://modernod.com/news/international-sports-vision-association-and-macuhealth-offer-new-educational-resource-on-sports-nutrition-for-your-eyes/2479270/The International Sports Vision Association (ISVA) and MacuHealth announced the launch of “Sports Nutrition for Your Eyes,” a new educational resource on the ISVA website designed to help educate athletes about how proper nutrition ca
- Novartis Terminates Three Trials of Beovu Despite Meeting Primary Endpoint of MERLIN Trialhttps://modernod.com/news/novartis-terminates-three-trials-of-beovu-despite-meeting-primary-endpoint/2479246/Novartis reported that Beovu met its primary endpoint in the phase 3 MERLIN trial, but decided to terminate the study due to higher rates of intraocular inflammation with frequent dosing intervals. Novartis reported the first interpretable year 1 results of the MERLIN trial, a 2-year study